<DOC>
	<DOCNO>NCT01492153</DOCNO>
	<brief_summary>This study conduct Asia . The aim study investigate safety efficacy NovoLet® human insulin delivery system outpatient setting .</brief_summary>
	<brief_title>NovoLet® Surveillance Study Using Human Insulin System Indonesia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes mellitus Type 2 diabetes mellitus Other type diabetes mellitus ( gestational , drug induce [ thiazide ] metabolic syndromerelated )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>